Novoste appoints Getz for Pacific Rim:
This article was originally published in Clinica
Executive Summary
Australian company Getz has agreed to oversee the commercialisation and distribution of Novoste's Beta-Cath system in Australia and New Zealand following a three- year agreement. The product is designed to inhibit restenosis by delivering radiation therapy to the artery immediately after an angioplasty procedure (see Clinica, No 866, p 15). According to Norcross, Georgia-based Novoste, the Beta-Cath system is the first vascular brachytherapy device to become commercially available in Australia. It is already on sale in Europe and undergoing clinical trials in the US.